Lupin rises on receiving approval from USFDA for Sevelamer Carbonate for Oral Suspension
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 908.00, up by 10.85 points or 1.21% from its previous closing of Rs. 897.15 on the BSE.
The scrip opened at Rs. 913.70 and has touched a high and low of Rs. 913.70 and Rs. 900.45 respectively. So far 5336 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 854.00 on 20-Dec-2021.
Last one week high and low of the scrip stood at Rs. 925.00 and Rs. 854.00 respectively. The current market cap of the company is Rs. 40748.27 crore.
The promoters holding in the company stood at 46.83%, while Institutions and Non-Institutions held 40.41% and 12.76% respectively.
Lupin has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Sevelamer Carbonate for Oral Suspension, 0.8 g and 2.4 g packets to market a generic equivalent of Renvela for Oral Suspension, 0.8 g and 2.4 g Packets of Genzyme. This product will be manufactured at Lupin's Goa facility in India.
Sevelamer Carbonate for Oral Suspension (RLD: Renvela for Oral Suspension) had estimated annual sales of $51.7 million in the U.S. (IQVIA MAT September 2021).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
